Total Payments
$8,138
2024 Payments
$385.82
Companies
22
Transactions
98
Medicare Patients
9,733
Medicare Billing
$601,210
Payment Breakdown by Category
Consulting$6,375 (78.3%)
Food & Beverage$1,763 (21.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,375 | 3 | 78.3% |
| Food and Beverage | $1,763 | 95 | 21.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic, Inc. | $4,430 | 5 | $0 (2024) |
| Medtronic Vascular, Inc. | $2,167 | 4 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $257.10 | 18 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $214.35 | 12 | $0 (2024) |
| Boston Scientific Corporation | $203.42 | 7 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $174.39 | 8 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $135.68 | 10 | $0 (2024) |
| ATRICURE, INC. | $104.35 | 4 | $0 (2024) |
| PFIZER INC. | $71.79 | 5 | $0 (2023) |
| Amgen Inc. | $63.93 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $385.82 | 20 | Novartis Pharmaceuticals Corporation ($104.20) |
| 2023 | $2,623 | 17 | Medtronic, Inc. ($2,314) |
| 2022 | $2,240 | 9 | Medtronic, Inc. ($2,100) |
| 2021 | $6.72 | 1 | United Therapeutics Corporation ($6.72) |
| 2020 | $2,333 | 15 | Medtronic Vascular, Inc. ($2,167) |
| 2019 | $92.63 | 7 | Janssen Pharmaceuticals, Inc ($35.13) |
| 2018 | $102.59 | 7 | BOSTON SCIENTIFIC CORPORATION ($25.75) |
| 2017 | $353.43 | 22 | E.R. Squibb & Sons, L.L.C. ($164.89) |
All Payment Transactions
98 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Cardiology | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $17.29 | General |
| Category: Cardiovascular | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $13.14 | General |
| Category: Cardiovascular | ||||||
| 11/06/2024 | ATRICURE, INC. | EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) | Food and Beverage | In-kind items and services | $41.12 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: DIABETES | ||||||
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $17.29 | General |
| Category: Cardiovascular | ||||||
| 10/24/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $30.68 | General |
| Category: General - Therapies_CRM | ||||||
| 10/22/2024 | ATRICURE, INC. | SYNERGY ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: Cardiology | ||||||
| 10/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/17/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: General - Therapies_CRM | ||||||
| 07/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/20/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/13/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.51 | General |
| Category: Cardiovascular | ||||||
| 01/30/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Cardiology | ||||||
| 01/02/2024 | Medtronic, Inc. | VENASEAL (Device) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: EndoVenous Therapies | ||||||
| 11/16/2023 | ATRICURE, INC. | SYNERGY ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/19/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: DIABETES | ||||||
| 09/29/2023 | Medtronic, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| 09/28/2023 | ATRICURE, INC. | SYNERGY ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/14/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 2,189 | 3,090 | $455,845 | $161,424 |
| 2022 | 23 | 2,676 | 3,721 | $431,690 | $149,468 |
| 2021 | 21 | 2,561 | 3,708 | $423,270 | $148,746 |
| 2020 | 26 | 2,307 | 3,197 | $417,710 | $141,572 |
Total Patients
9,733
Total Services
13,716
Medicare Billing
$601,210
Procedure Codes
104
All Medicare Procedures & Services
104 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 383 | 564 | $73,320 | $49,300 | 67.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 340 | 434 | $43,400 | $24,769 | 57.1% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 272 | 450 | $63,000 | $22,472 | 35.7% |
| 33208 | Insertion of pacemaker and upper and lower heart chamber electrode | Facility | 2023 | 34 | 34 | $54,400 | $13,530 | 24.9% |
| 93284 | Programming of multiple lead implantable defibrillator system | Office | 2023 | 57 | 90 | $18,000 | $6,353 | 35.3% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 142 | 158 | $50,560 | $6,253 | 12.4% |
| 93283 | Programming of dual lead implantable defibrillator system | Office | 2023 | 56 | 78 | $13,650 | $5,180 | 37.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 311 | 472 | $25,960 | $4,197 | 16.2% |
| 33228 | Removal and replacement of dual lead permanent pacemaker | Facility | 2023 | 16 | 16 | $19,200 | $3,941 | 20.5% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 88 | 159 | $19,875 | $3,683 | 18.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 41 | 56 | $6,160 | $3,347 | 54.3% |
| 33264 | Removal and replacement of multiple lead defibrillator | Facility | 2023 | 11 | 11 | $16,500 | $3,118 | 18.9% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 32 | 35 | $9,100 | $2,720 | 29.9% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 125 | 196 | $9,800 | $2,629 | 26.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 18 | 19 | $4,180 | $1,906 | 45.6% |
| 93279 | Programming of single lead pacemaker system | Office | 2023 | 22 | 35 | $4,200 | $1,570 | 37.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $2,520 | $1,355 | 53.8% |
| 93281 | Programming of multiple lead pacemaker system | Office | 2023 | 12 | 20 | $3,200 | $1,131 | 35.3% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 18 | 18 | $2,520 | $1,039 | 41.2% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 38 | 38 | $3,800 | $640.92 | 16.9% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Facility | 2023 | 13 | 32 | $3,200 | $602.57 | 18.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 80 | 92 | $3,220 | $514.35 | 16.0% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 26 | 27 | $1,755 | $511.78 | 29.2% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 16 | 16 | $1,900 | $316.64 | 16.7% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Facility | 2023 | 12 | 14 | $1,400 | $228.90 | 16.4% |
About Dr. Bartolomeo Giannattasio, MD
Dr. Bartolomeo Giannattasio, MD is a Cardiovascular Disease healthcare provider based in Middleburg Heights, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174552251.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bartolomeo Giannattasio, MD has received a total of $8,138 in payments from pharmaceutical and medical device companies, with $385.82 received in 2024. These payments were reported across 98 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($6,375).
As a Medicare-enrolled provider, Giannattasio has provided services to 9,733 Medicare beneficiaries, totaling 13,716 services with total Medicare billing of $601,210. Data is available for 4 years (2020–2023), covering 104 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Clinical Cardiac Electrophysiology
- Location Middleburg Heights, OH
- Active Since 07/01/2006
- Last Updated 01/22/2014
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1174552251
Products in Payments
- ELIQUIS (Drug) $312.30
- LifeVest (Device) $174.39
- Micra (Device) $167.37
- XARELTO (Drug) $135.68
- ENTRESTO (Drug) $129.16
- LEQVIO (Drug) $85.19
- VIGILANT X4 CRT-D (Device) $82.80
- SYNERGY ABLATION SYSTEM (Device) $63.23
- Impella (Device) $60.00
- VERQUVO (Drug) $53.34
- Repatha (Biological) $50.53
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) $41.12
- JARDIANCE (Drug) $35.25
- WATCHMAN (Device) $25.75
- PRALUENT (Drug) $22.94
- V-LOC 180 (Device) $22.90
- VIGILANT (Device) $21.46
- GlideWire (Device) $20.05
- SAMSCA (Drug) $17.84
- OPSUMIT MACITENTAN (Drug) $16.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.